In this episode senior associate and patent attorney Paul Roscoe, and partner, solicitor and trade mark attorney Chris Hoole, are joined by 3D printing specialist and CEO/co-founder of Promake, Professor Jason Laing.
This episode will help manufacturers to understand the IP risks associated with 3D printing, how smart materials could provide anti-counterfeiting measures, and the direction of innovation in this technology area.
If you have any questions on this episode, IP in general, or would like to suggest a topic, please contact us at ip@appleyardlees.com.
Listen here: https://…
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
Stevenage, UK, 26 April 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as independent Non-Executive Chair.
Jonathan’s appointment reflects the maturation of the company, having closed its series A financing of £16m in late 2022.
Jonathan brings over 20 years of experience in the biotech and pharma industries focused on strategic partnerships (investments, licensing, and M&A)…
Click here to view the April 2023 edition of The Meeting Place
• Agreement grants access to patient genotypes and clinical data curated by Professor Ammar Al-Chalabi’s Group based at King’s College London
• Motor Neurone Disease (MND) Association supports new analysis of patient data to bring cutting edge analysis tools to improve understanding of disease
• Enables PrecisionLife to establish precision neuroscience R&D partnerships to advance new patient stratification biomarkers, diagnostics and treatment approaches
Oxford and London, UK, 25 April 2023 – The techbio company PrecisionLife (http://www.precisionlife.com/) announces it has agreed a data…
Cambridge and Saffron Walden, UK, 21st April 2023 / Sciad Newswire / Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period. This growth was achieved organically, coincided with the challenging backdrop of the COVID-19 pandemic and is a testament to the company’s excellent reputation and commitment to delivering high-…
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
● Vad Lazari Ph.D., appointed to newly created position of VP of Biology, based in Stevenage, UK
● Joins from Charles River and brings two decades of drug discovery experience including at Pfizer and BioFocus DPI
● Will be responsible for leading the biology to support NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) as treatments for Parkinson's and…
Funding targets a critical unmet clinical need to treat autoimmunity, which affects around 300 million people globally
Awarded as part of £25 million Innovate UK Biomedical Catalyst fund
Cambridge, UK – 19 April 2023 – Biotechnology company Maxion Therapeutics (‘Maxion’) today announced it has been awarded a prestigious GBP £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. The funds will support the use of Maxion’s proprietary KnotBody® platform to develop antibodies to treat autoimmune diseases (AID)…
- Sharpest rise in CFO optimism since 2020;
- Survey shows biggest decline on record for CFOs’ perceptions of external uncertainty;
- Brexit and energy risks ease;
- CFOs see artificial intelligence driving investment and productivity, but are divided on impact on jobs within the workforce.
Sentiment among finance leaders of the UK’s largest firms has improved significantly since the start of the year, according to Deloitte’s UK CFO Survey Q1 2023.
A net 25%1 of CFOs are more optimistic about the financial prospects of their business than they were three months ago. Having run well below the…
20th March 2023 Nijmegen, The Netherlands and Biocity Nottingham UK
Alveron Pharma announces that it has commenced a Phase 1 clinical study for OKL-1111, a new drug for the treatment of Intracranial Haemorrhage (ICH) and other life-threatening bleeds associated with the use of anticoagulants or platelet inhibitors. The clinical trial is taking place in the UK and will investigate safety, pharmacokinetics and pharmacodynamics in man.
ICH is a devastating condition with a 30-50% mortality rate and is also responsible for approximately 50% of disability associated with stroke…
Do you have a winning commercialisation strategy?
If you are a startup that:
- Is developing therapeutic innovations
- Has obtained a first proof-of-concept OR a £1-3m funding
- Has integrated digital technologies (ML/AI) in the R&D workflow OR is planning to
Apply to SBC Catalyser programme!
You'll end the free 8-week programme with:
- A refined commercialisation strategy to go from prototype to commercially-viable product
- A better understanding of how to improve / embed digital technologies (ML/AI) to accelerate your R&D
- Access to SBC extensive network of experts, mentors…